OssDsign

In the notice convening the annual general meeting in OssDsign AB (publ) (the “Company”), to be held on 11 June 2025, the nomination committee proposed re-election of Simon Cartmell (also proposed to be re-elected as chairman), Christer Fåhraeus, Jill Schiaparelli and Newton Aguiar, and new-election of David Jern, as ordinary members of the board of directors.

The nomination committee has been informed that Newton Aguiar has declined re-election. As a result, the nomination committee proposes that Tomas Blomquist shall be elected as a new board member (i.e. instead of re-election of Newton Aguiar). The nomination committee further proposes that Tomas Blomquist shall receive the same board remuneration as was proposed to be payable to Newton Aguiar (i.e. SEK 300,000).

The nomination committee’s other proposals as presented in the notice convening the annual general meeting remain unchanged.

Information about proposed new board member

Name: Tomas Blomquist

Born: 1970

Education and experience: Tomas Blomquist has more than 30 years of international experience in the healthcare sector, with a particular focus on Life Science Tools, Diagnostics, and Medtech. He has held executive positions at global companies such as Abbott, Roche, Johnson & Johnson, and Analyticon Biotechnologies. Tomas served as CEO and President of Biotage AB from 2019 until January 2024. He has also been a member of management teams and boards in several international companies. Tomas possesses extensive expertise in corporate strategy, vision and culture, team and leadership development, business model innovation, M&A, internationalization, organizational design, and commercialization. He holds an education from the Stockholm School of Economics, where he completed the Advanced Management Program as well as the Executive Management Program.

Other current roles: Tomas is a board member of Nolato AB (since May 2021).

Tomas is independent in relation to the company and its management as well as in relation to the company's major shareholders. He owns no shares in OssDsign.

Composition of nomination committee

The nomination committee is composed of the chairman of the board of directors of the Company (i.e. Simon Cartmell), Karl Tobieson (appointed by Linc AB and elected chairman of the nomination committee), Emanuel Eriksson (appointed by FSG Fund) and Stefan Hansson (appointed by TAMT AB). As compared to the date of issuance of the notice to attend the annual general meeting, and as a result of the reduced shareholding of Karolinska Development AB, Karl Tobieson has replaced Viktor Drvota as member and chairman of the nomination committee.

For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Mob: +46 73 382 43 90
morten.henneveld@ossdsign.com

Certified Adviser:

The Company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ).

Publication
This information was submitted for publication, through the agency of the contact person set out above, on 9 June 2025, 14:00 CEST.

About OssDsign

OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.